PDXliver: a database of liver cancer patient derived xenograft mouse models

Sheng He1,3,4†, Bo Hu2†, Chao Li3, Ping Lin3,4, Wei-Guo Tang2, Yun-Fan Sun2, Fang-You-Min Feng1,3,4, Wei Guo2, Jia Li1,3,4, Yang Xu2, Qian-Lan Yao5, Xin Zhang2, Shuang-Jian Qiu2, Jian Zhou2, Jia Fan2, Yi-Xue Li1,3, Hong Li3* and Xin-Rong Yang2*

Abstract

Background: Liver cancer is the second leading cause of cancer-related deaths and characterized by heterogeneity and drug resistance. Patient-derived xenograft (PDX) models have been widely used in cancer research because they reproduce the characteristics of original tumors. However, the current studies of liver cancer PDX mice are scattered and the number of available PDX models are too small to represent the heterogeneity of liver cancer patients. To improve this situation and to complement available PDX models related resources, here we constructed a comprehensive database, PDXliver, to integrate and analyze liver cancer PDX models.

Description: Currently, PDXliver contains 116 PDX models from Chinese liver cancer patients, 51 of them were established by the in-house PDX platform and others were curated from the public literatures. These models are annotated with complete information, including clinical characteristics of patients, genome-wide expression profiles, germline variations, somatic mutations and copy number alterations. Analysis of expression subtypes and mutated genes show that PDXliver represents the diversity of human patients. Another feature of PDXliver is storing drug response data of PDX mice, which makes it possible to explore the association between molecular profiles and drug sensitivity. All data can be accessed via the Browse and Search pages. Additionally, two tools are provided to interactively visualize the omics data of selected PDXs or to compare two groups of PDXs.

Conclusion: As far as we known, PDXliver is the first public database of liver cancer PDX models. We hope that this comprehensive resource will accelerate the utility of PDX models and facilitate liver cancer research. The PDXliver database is freely available online at: http://www.picb.ac.cn/PDXliver/

Keywords: Liver cancer, PDX model, Drug response, Database

Background

Patient-derived xenograft (PDX) models are generated by directly transplanting cancer patients’ tumor samples to immune-compromised mice. It has been widely applied to multiple cancer types, such as breast cancer, lung cancer and colon cancer [1–4]. PDX models recapitulated the histologic, genomic, expression and biological characteristics of the corresponding primary tumors [5–8].

Additionally, the response of PDX models to drug treatment are remarkable correlated with clinical outcome, which made it possible to establish personalized xenograft model to help make therapeutic decision and guide the cancer treatment [9–12]. For example, Manuel Hidalgo et al. generated 14 PDX models for 14 patients and treated tumorgrafts with 63 different drugs; an effective drug in the PDX model was identified for 12 patients [13]. Hui Gao et al. have established ~1000 PDX models involving six cancer types, used these models to in vivo screen drug and compounds, and successfully reveal some resistance mechanisms [14]. Therefore, PDX models are thought to be the best pre-clinical models for translational drug development in cancer research.

* Correspondence: lihong01@sibs.ac.cn; yang.xinrong@zs-hospital.sh.cn
†Equal contributors
3CAS Key Laboratory for Computational Biology, CAS-MPG Partner Institute for Computing Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
2Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai 200032, China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Liver cancer is the second most common causes of cancer-related deaths with an estimated nearly, 29,200 new cases and 40,710 fatalities occurred United States in 2017 [15], with the highest incidence rates reported in China. For patients with unresectable liver cancers, sorafenib is the only FDA approved standard first-line drug. However, sorafenib only improved the overall survival by nearly 3 months [16, 17]. The current genome sequencing revealed that 28% of liver cancer patients harbored at least one targetable mutation by FDA-approved drugs [18]. In future, these patients may benefit from targeted treatment if the effectiveness of drug is further validated by PDX models.

The first liver cancer PDX model was reported in 1996, but this field progressed slowly due to the very low engraftment rate [19–23]. In the last five years, the engraftment rate was increased to nearly 40% by improved experimental methods and many liver cancer PDX models had been generated. A cohort of 65 stable liver cancer PDX models were established and revealed that lenvatinib, a FGFR1 inhibitor, presented better therapeutic effect than sorafenib in the models expressing high levels of FGFR1 gene [24]. Although PDX models have achieved useful results in liver cancer treatment, there still exist some problems, such as engraftment failure for 59% patients, long-time (2–4 months) for the tumor to engraft. With more cumulated PDX models, it will be feasible to predict the drug response of new patients. Such algorithms have been used in large-scale cancer cell line studies. Machine learning or regression models were built to predict drug sensitivity based on molecular profiles, including gene expression, somatic mutations and copy-number alterations [25, 26]. Nevertheless the current studies of liver cancer PDXs are scattered in different literatures. An integrated database with unified format will facilitate the application of liver cancer PDXs.

Here we built a database PDXliver, which collected liver cancer PDX models and provided comprehensive genome, transcriptome and drug response data. Currently PDXliver contains 116 PDX mouse models from 116 Chinese liver cancer patients, 26 of which have drug response data. Sixty-five models were curated from public papers and others came from in-house PDX platform. We also developed tools to help users to explore the omics data of PDX models. This new resource will facilitate the drug sensitivity prediction and precision medicine of liver cancer.

**Construction and content**

**Implementation**

We integrated PDX models from the in-house PDX experimental platform and public literatures [24]. Models that came from the same batch or literature were called a dataset. To facilitate the management of massive PDX mouse models, we also set naming rules for patients and xenografts. Each patient was randomly assigned an identifier (e.g.: PD0001). Mice from this patient were named using the combination of patient's identifier and the passage number. F1 is the 1st-passage xenograft, F2 is the 2nd-passage, and so on. Clinical, molecular and drug sensitivity data were stored into database if they were available. Three main function blocks (search, browse, tools) were developed to display the characteristics of PDX models (Fig. 1a).

The PDXliver database was built in RedHat Linux server (4.4.7–11) and the web interface was implemented using a combination of JavaScript and PHP scripts. All the data were stored in a MySQL (version 5.7.9) database. Data processing and visualization were performed by R language or JavaScript plugin. PDXliver can be accessed via the major browsers such as Chrome, Safari, Edge, and Firefox.

**Establishment of PDX models**

4–5 weeks old male non-obese diabetic severe combined immunodeficiency (NOD/SCID) mice as transplant recipient models were raised in the aseptic environment. Liver cancer tumor samples were cut into pieces within 1 h after removal from patients. Tissue fragments were incubated in DMEM medium supplemented with 50% Matrigel™ (BD; 356,234), 10 ng/mL epidermal growth factor (Gibco; PHG0314), 10 ng/ml basic fibroblast growth factor (Gibco; PHG0264), 100 U/mL penicillin, and 100 U/mL streptomycin for 30 min. Tumor tissues with the incubation mix (Matrigel plus growth factors) were transplanted into the right flanks of mice (n = 3; 4–5 weeks old, Shanghai Institute of Material Medicine, Chinese Academy of Science) subcutaneously with a No. 20 trocar. Animal care and experimental protocols were approved by the Shanghai Medical Experimental Animal Care Commission. The tumor growth was recorded three times a week from the measurement of length (L) and width (W) with caliper and calculated as tumor volume (TV, mm3) = 0.5 × L × W2 (mm). To explore the intrinsic sensitivity of the first-line drug of treatment for liver cancer, some PDX models were randomly selected for drug experiments. To estimate the performance of drugs, a criterion named Tumor Growth Inhibition (TGI) was used. Tumor Growth Inhibition is equal to the ratio of the experimental group tumor volume and the control group tumor volume. When the tumor in the control group mice grew to the definite dimension, both the control and experimental group mice were killed and fresh tumor samples were obtained to do microarray or next generation sequencing. All clinical data was anonymized to protect patient privacy.
Collection of public PDX models

To expand the capacity of our database, we collected clinical and molecular information of PDX models from literatures. PubMed database was searched using keywords “liver cancer” or “hepatocellular carcinoma”, and “PDX” or “patient-derived xenograft”. It returned 148 records by Feb 10, 2018. After the manual check, 52 literatures established liver cancer PDX mice from patients, but only one of them provided both clinical information and high-throughput molecular data [24]. If the original authors had uploaded their experimental data to GEO or other databases, we downloaded the raw data and processed it into a unified format (detailed methods were described in the next paragraph). If raw data was not available but there was processed data in supplementary material, we directly stored the processed data into database.

Data processing

The raw data was processed into unified format before storing into database.

1) Affymetrix genome-wide human SNP 6.0 array

Raw data were stored in CEL files. Genotypes were called by the CRLMM algorithm in R package “oligo”. SNP identifiers were mapped to dbSNP ID and gene symbols by R package “pd.genomewidesnp.6”.

2) Exome sequencing

Raw data were stored in FASTQ files. Low-quality reads were filtered, and then the remained reads were mapped to human genome (hg19) by BWA algorithm. Duplicated reads were removed by the picard tool. SNVs and indels were called by GATK based on the GATK best practices. Somatic mutations were identified by VarScan2 if the paired tumor and control samples were available. The potential functional effects of mutations were annotated by ANNOVAR. We collected 72 significantly mutated genes from 6 published genomes studies of liver cancer patients. Functional mutations (non-synonymous, splicing, stop-gain and stop-loss SNVs; exonic indels) in these significantly mutated genes were stored into database.

3) Affymetrix gene expression array

Raw data were stored in CEL files. Expressions of probes were estimated by the Robust Multichip Average algorithm in R package “affy”, and normalized by quantile normalization. For genes with multiple probes, the mean of all probes was used as gene expression. The gene expression genes were log2 transformed and then stored into database.

4) RNA sequencing
Raw data were stored in FASTQ files. Low-quality reads were filtered using NGQC Toolkit. Then high-quality reads were mapped to human genome (hg19). Gene expression levels were estimated by the RSEM algorithm, and normalized by the trimmed mean of M-values (TMM) normalization method.

For most of the in-house DPX models, raw data have been submitted to public repositories (GEO). PDXliver webpages provide links to the public repositories.

Data statistics
The PDXliver database was designed to provide a data storage, search, and analysis system for liver cancer mouse xenografts (Fig. 1a). Currently, it contained three datasets. One dataset were obtained from a public literature [24]. Another two datasets came from our in-house PDX experimental platform (the Liver Cancer Institute of ZhongShan Hospital, Fudan University, Shanghai, China); some PDX models are firstly publicly available in PDXliver. Table 1 gives the source of each dataset, the number of PDX models with molecular profiles or drug treatment. A total of 116 patients have stable PDX models, some patients have multiple serially passed xenografts. All patients have been comprehensively annotated with clinical information, such as age, gender, virus infection and tumor stage (Table 2, Fig. 1b). Since all patients are Chinese, most of them are HBV positive (n = 88). Hepatocellular carcinoma (HCC) is the major histopathologic subtype (n = 100), followed by cholangiocarcinoma (n = 11). A part of models have genome-wide expression profiles (n = 88), germline variations (n = 40), somatic mutations (n = 69) and copy number alterations (n = 42). Expression profiles of 72 HCC were available and they were classified into three subgroups using a previous public method [27]: S1 (23.6%), S2 (23.6%) and S3 (41.7%) (Fig. 1c). TP53 (69.5%) is the most frequently mutated gene in liver cancer PDX models; its frequency is higher than the reported frequency (25%~35%) in liver cancer patients [28, 29]. Mutation frequency of another four genes (APOB, CTNNB1, AXIN1, TSC2) are higher than 10%. We also provide histological staining (n = 40), tumor growth curve (n = 40), and drug response data (n = 26) for the in-house PDX models.

Utility and discussion
Data browse and search
To help users quickly understand and query PDXliver, we designed the “Browse” and “Search” pages (Fig. 2).

The “Browse” page allows users to query PDX models by histopathologic subtype, tumor grade, virus infection and data source (Fig. 2a). Users can select the combination of multiple conditions. Results will be returned in a list, each row represents a model including some summary information. Meanwhile, users can go to the detailed page of PDX model by clicking the hyperlink.

The “Search” page contains six query frames (Fig. 2b). Firstly, users can exactly find the PDX mouse model if they know its identifier (e.g. PD0001). It will link to the detailed page of PDX model, including clinical characteristics of the associated patient, engraftment conditions, drug treatment, histopathology image and tumor growth curve (Fig. 3a). Some entries may be empty if the data is unavailable. A part of transplantable xenograft lines have been stably maintained over multiple passages, e.g. F1 to F4 generations of PD0003. Our previous work have proved that the histological, genomic and transcriptomic characteristics of PDX mice were remarkable stable across sequential passages. The result page also showed the similarity of histopathology images among serially transplanted xenografts (Fig. 3b). Secondly, users can retrieve PDX mice that have been treated by the given drug. After querying a drug name, a result table will be returned to display the model identifier, drug dose, frequency and duration of drug treatment, and drug response rate (TGI). Thirdly, user can obtain the expression profile of one gene by querying its gene symbol. Expression values in all PDX models are visualized by a barplot (Fig. 3c). Fourthly, users can query a single nucleotide polymorphism (SNP) site by its dbSNP ID. The result page contains the basic information of SNP, such as location and associated gene; it also shows its

| Data Set | Patient | Transcriptome | Genome | Drug | Source | Reference |
|----------|---------|---------------|--------|------|--------|-----------|
| Dataset1 | 46      | 40            | 40     | 21   | ZhongShan Hospital | unpublished |
|          |         | Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) | Affymetrix Genome-Wide Human SNP 6.0 Array | 13 Exome sequencing |
| Dataset2 | 65      | 43            | 42     | 0    | WuXi AppTech | [24] |
|          |         | Affymetrix Human Gene Expression Array (GPL15207) | Affymetrix Genome-Wide Human SNP 6.0 Array | 56 Exome sequencing |
| Dataset3 | 5       | 5             | 5      | 5    | ZhongShan Hospital | unpublished |
|          | RNA sequencing | | | | | |
genotypes in different PDX models. Fifthly, users can browse somatic mutations of a given gene in liver cancer PDXs. The result page shows chromosome position, reference and alternative alleles, mutation type, amino acid change, and potential function effect (Fig. 3d). The last query item allows users to search the copy number alterations with gene symbol. It will return the detail copy number variations in PDX models if the associated data are available (Fig. 3e).

**Analysis tools**

**Visualization of molecular profiles**

The “HeatMap” tool allows users to intuitively visualize the molecular profiles of PDX models. To draw a customizable heatmap, users need to select a dataset and a molecular type, and provide a list of genes (Fig. 4a). There are three alternative molecular types: gene expression, somatic mutation and somatic copy number alteration (SCNA). The available molecular type may be different based on the source of datasets. For example, dataset1 has gene expression and somatic mutation data but does not have SCNA; therefore SCNA is not an optional molecular type after selecting dataset1. For somatic mutation, the heatmap only plots the significantly mutated genes in liver cancer patients [30]. For gene expression and SCNA, users need to provide a list of genes by entering gene symbols in the text area or uploading a file that contains gene symbols. The gene symbols should be separated by comma or space.

Once users input these necessary parameters, a customized heatmap will be plotted. Figure 4b shows an example of expression heatmap. Each row is a gene and each column is a PDX mouse model. Gene expression values are converted to Z-score. Color represents the Z-score of gene expression values. Red indicates high expression and green means low expression. In a heatmap of copy-number alterations, the variation-type (amplification or deletion) and the number of copy number variations are respectively painted with different colors (Fig. 4c). The heatmap of somatic mutation is similar, with color reflected different types of somatic mutation, such as frame-shift indels and non-synonymous SNVs (Fig. 4d).

**Differential expression analysis**

The purpose of this tool is to identify genes whose expressions are significantly different between two groups of PDX models. Expression profiles from different datasets may have batch effect; pathological subtypes of liver cancer may display different expression patterns. Therefore, we provided two parameters (dataset and

---

**Table 2 Clinical information of 116 liver cancer patients**

| Clinical indexes     | No. of Patients |
|----------------------|-----------------|
| Age (y) < 50         | 43              |
| Age (y) ≥ 50         | 73              |
| Gender Female        | 20              |
| Gender Male          | 96              |
| Tumor differentiation|                 |
| Early stage (I-II)   | 16              |
| Late stage (III-IV)  | 96              |
| HBV Positive         | 88              |
| HBV Negative         | 16              |
| HCV Positive         | 1               |
| HCV Negative         | 47              |
| Tumor encapsulate    |                 |
| Complete             | 30              |
| None                 | 20              |
| Tumor subtype        |                 |
| Hepatocellular cancer| 100             |
| Cholangiocarcinoma   | 11              |
| Other                | 5               |

---

Fig. 2 Screenshots of the “Browse” and “Search” pages. **a** “Browse” page. PDX models can be browsed by histopathologic subtype, tumor grade, virus infection state, and data sources. **b** “Search” page. PDX models can be queried by the model identifier and drug name. Gene expression, germline variants, somatic mutation and copy number alterations can be retrieved by gene symbol (as shown in the red oval). An example of corresponding result was showed in the lower right.
histological type) to make the selected PDX models more comparable. Then users can classify PDX models into two groups by their clinical indicators, such as “response to sorafenib” and “status of HBV infection”. All genes were tested by the given statistical method. Significant genes were selected out by the user defined $P$-value and fold change.

To illustrate the use of this tool, we tried to find genes associated sorafenib response by comparing sensitive PDXs and resistant PDXs. We selected “dataset1”, “Hepatocellular carcinoma” and “Drug response to sorafenib” in the first three steps. Then the webpage showed 16 PDX mice whose responses to sorafenib were evaluated by tumor growth inhibition (Fig. 4e).

According to the criteria of the Division of Cancer Treatment (NCI), PDXs whose TGI < 20% were defined as having response and PDXs whose TGI > 50% were defined as tumor progression. Therefore, we selected 3 sensitive PDXs and 5 resistant PDXs in the step 4. We compared the sensitive group and resistant group by the two-tailed T-test. There were 77 significantly differential genes between two groups (Fig. 4f) ($P < 0.01$, FoldChange$> 2$), indicating potential association with sorafenib response. We also realized that the statistical power might be low due to the small number of PDX models, more PDXs are needed to make the results more reliable. Our tool will make it easier to get the analysis results of new data.
**Conclusion**

As a preclinical model, PDX models represent the original features of patient tumors in many ways and have been shown to be predictable for the drug response of patients. Nevertheless, the progress of PDX models is relatively slower in liver cancer than it in other cancer types, such as breast cancer and lung cancer. It is important to establish a comprehensive PDX cohort that represents the diversity of the human liver cancer patients. The PDXliver is designed to provide a
bioinformatic platform to collect and analysis liver cancer PDXs data. In recent years, genomic and transcriptomic studies of human liver cancer patients have made great contributions. The genomic studies revealed mutation landscape of liver cancer, promoting the understanding of cancerogenesis. The transcriptomic studies classified liver cancer into different expression subtypes, promoting the understanding of cancer heterogeneity. However, these studies lack of the information of treatment response. It is difficult to directly associate gene with drug through patients. PDXliver stores hundreds of liver cancer PDX models, which covers the significantly mutated genes and expression subtypes of liver cancer patients. Therefore, PDXliver retains the heterogeneity of human liver cancers. It will be valuable for precision medicine.

To facilitate the utility of liver cancer PDX mice models, PDXliver has several features. Firstly, PDXliver has the largest number of liver cancer PDX models so far and the number will continue to increase in future. Secondly, PDXliver categorizes all clinical data, genomic data, transcriptome data and drug responses data for easy search and access, which makes users quickly gain insights into the models. Thirdly, the analysis tool allows users to compare the molecular profiles among multiple PDX models. We expect that PDXliver will become a very useful resource for liver cancer PDXs research.

As far as we known, PDXliver is the first public database for liver cancer PDX mice models. We searched PubMed and did not find other databases specifically designed for PDX mouse models. One similar database, Mouse Tumor Biology Database (MTB http://tumor.informatics.jax.org/mtbwi/index.do), provides information on diverse mouse models for human cancers. MTB contains 440 PDX models from the Jackson laboratory, but only 2 models originated from liver (hepatoid adenocarcinoma). Another software cBioPortal provides a public framework for storing and visualizing cancer genomic data, which generated from tissue biopsy samples of cancer patients. However, PDXliver focuses on the liver cancer patient-derived xenograft models; the combination of drug sensitivity and omics data will be more useful for pharmacogenomics research.

Although PDXliver is the most comprehensively resources for liver cancer PDX models, there are still limitations. Expression profiles in different datasets were generated from different experiment platforms or different analysis methods, which may be not comparable. Furthermore, the public dataset didn’t have drug response data. Even for the in-house PDX models, the major drug is sorafenib and only a few models have drug sensitivity values for multiple drugs. We plan to treat PDX models with more drugs in future. An ongoing project in our lab has constructed another 50 liver cancer PDX models with drug response. These models and future new models will be stored into PDXliver. More models with available drug response data will make this database much more useful for drug sensitivity prediction. In addition, some important information such as therapeutic effects and survival time of patients are not available due to the short follow-up time, we will add these data in future to enrich the database contents.

**Abbreviations**

GEO: Gene Expression Omnibus; HCC: Hepatocellular carcinoma; MTB: Mouse tumor biology database; NOD/SCID: Non-obese diabetic severe combined immunodeficiency; PDX: Patient-derived xenograft; TGI: Tumor growth inhibition

**Funding**

This work was supported by National Key R&D Program of China [2018YFC0902403], the State Key Program of National Natural Science of China [81530077], the National Natural Science Foundation of China [81602543, 81627839, 81372317, 81472676, 81772551 and 81572823], the Projects from the Shanghai Science and Technology Commission [14DZ1940300, 14411970200], and “Strategic Priority Research Program” of the Chinese Academy of Sciences [XDA12020103 and XDA12020105]. The funding body had put into the design of the study and collection, analysis and interpretation of data.

**Availability of data and materials**

PDXliver is freely-accessible via the URL http://www.picb.ac.cn/PDXliver/. The raw expression and SNP array data of in-house PDX models have been deposited in GEO database (https://www.ncbi.nlm.nih.gov/geo, Expression: GSE90565; SNP: GSE90651).

**Authors’ contributions**

SH wrote the manuscript and developed the database. BH designed and conducted the experiments. HY, YXR, LXY and JF conceived the study and conducted the review of data analysis. PL, FYMY, JL and QLY tested the database, and provided feedback on the design. CL, WGT, SFY, GW, XY, XZ, SJQ and JZ participated in sample collection and the establishment of PDX model. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the ethics board at the Liver Cancer Institute of Zhongshan Hospital, Fudan University. All participants provided written informed consent for their material to be turned into patient-derived xenograft.

All mouse experiments have been regulate according to the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the Institutional Animal Care and Treatment Committee of Fudan University, and have been performed in accordance with the Home Office license awarded to JF.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1 School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China. 2 Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai 200032, China. 3 CAS Key Laboratory for Computational Biology, CAS-MPG Partner Institute for Computing Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China. 4 University of the Chinese Academy of Sciences, Beijing 100049, China. 5 School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200031, China.
References

1. Whittle JR, Lewis MT, Lindeman GJ, Visvader JE. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015;17(1).

2. Valtorta S, Mero M, Prisinzano G, Bertolini G, Tomoreto M, Raccagni I, Pastorino U, Roz L, Sozzi G, Moreo RM. Metabolic evaluation of nonsmall cell lung cancer patient-derived xenograft models using 18F-FDG PET: a potential tool for early therapy response. J Nucl Med. 2017;58(1):42–7.

3. Kim HY, Kim J, Ha TH, Bang OS, Lee WS, Hong S. Evaluation of anti-tumorigenic activity of BPB against colon cancer with patient-derived tumor xenograft model. BMC Complement Altern Med. 2016;16(1):473.

4. Sivanand S, Pena-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamazi S, McBride DJ, Gillen J, Wolff NC, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med. 2012;4(137):137ra75.

5. Solors D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73(17):5315–9.

6. Jung KH, Zheng HM, Jeong Y, Choi MJ, Lee H, Hong SW, Lee HS, Son MK, Lee S, Hong S, et al. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor. Cancer Lett. 2013;328(1):176–87.

7. Huang PW, Tsai SC, Luo TY, Lin WY. Therapeutic efficacy of 188Re-211At-PHBMC in a canine model of murine hepatocellular carcinoma. Ann Nucl Med. 2012;27(6):532–7.

8. Li Y, Tang Z, Ye S, Liu Y, Chen J, Xue Q, Huang X, Chen J, Bao W, Yang J, et al. Establishment of human hepatocellular carcinoma cell line with spontaneous pulmonary metastasis through in vivo selection. Zhonghua Yi Xue Za Zhi. 2002;82(9):601–7.

9. Fichtner I, Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73(17):5315–9.

10. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MEK as one mechanism for drug resistance. Eur J Cancer. 2011;47(8):1231–43.

11. Henriksen E, Balderstorp B, Borg A, Kjellen E, Alkervall J, Wennerberg J, Wåhlberg P. p53 mutation and cyclin D1 amplification correlate with displasia sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol. 2006;45(3):300–5.

12. Peltonen JK, Vahakangas KH, Helipi H, Bloigu R, Paakko P, Turpeenniemi-Hujanen T. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study. Head Neck Oncol. 2011;3:20.

13. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Straw S, Wick MJ, Martell J, Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011;10(8):1311–6.

14. Gao H, Korn JM, Ferretti S, Monahan JE, Wang YZ, Singh M, Zhang C, Schnell C, Yang GZ, Zhang Y, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21(1):1318–25.

15. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JP, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Lancet. 2008;372(9632):123–9.

17. Kalinina O, Marchio A, Urbanski AI, Tarkova AB, Rebbani K, Granov DA, Couchy G, Meiller C, Shinde J, Soysouvanh F, et al. Exome sequencing of advanced cancer. Mol Cancer Ther. 2011;10(8):1311–6.

18. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebobiu S, Couchy G, Meiller C, Shinde J, Soysouvanh F, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505–11.

19. Sun FX, Tang ZY, Liu KD, Ye SL, Xue Q, Gao DM, Ma ZC. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer. 1996;66(2):239–43.

20. Yan M, Li H, Zhao L, Zhang L, Ge C, Yao M, Li J. Establishment of NOD/SCID mouse models of human hepatocellular carcinoma via subcutaneous transplantation of histologically intact tumor tissue. Chin J Cancer Res. 2013;25(3):289–98.

21. Ammengal C, Tarafa G, Boix L, Sole M, Queralt R, Costa D, Bachs O, Bruix J, Capella G. Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. Clin Cancer Res. 2004;10(6):2150–7.

22. Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res. 2006;12(14 Pt 1):456–14.

23. Xin H, Wang K, Hu G, Xie F, Ouyang K, Tang X, Wang M, Wen D, Zhu Y, Qin X. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts. PLoS One. 2014;9(1):e85308.

24. Gu Q, Zhang B, Sun H, Xu Q, Tan Y, Wang Y, Luo Q, Xu W, Yang S, Li J, et al. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. Oncotarget. 2015;6(24):20160–76.

25. Tettler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcorioli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338–50.

26. Stebbing J, Paz K, Schwarz G, Weisler LH, Maki R, Pollock RE, Morris R, Cohen R, Shankar A, Blackman G, et al. Patient-derived xenografts for individualized care in advanced carcinoma. Cancer. 2014;120(13):2066–15.

27. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeja K, Hashimoto M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69(18):7385–92.

28. Pilot N, Grunberger T, Langle F, Mittlbock M, Perisanidis B, Kappel S, Wolf B, Starling P, Kuhler I, Muhlbaier F, et al. Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 research group study. Eur J Surg Oncol. 2015;41(5):683–9.

29. Kalinina O, Marchio A, Urbanski AI, Tarkova AB, Rebbani K, Granov DA, Dejane A, Generalov MI, Pineau P. Somatic changes in primary liver cancer in Russia: a pilot study. Mutat Res. 2013;755(2):90–9.

30. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Totoki Y, Liu Q, Leng X, et al. Exome sequencing of advanced cancer. Mol Cancer Ther. 2011;10(8):1311–6.

31. Val药材 S, Moro M, Prisinzano G, Bertolini G, Tomoreto M, Raccagni I, Pastorino U, Roz L, Sozzi G, Moreo RM. Metabolic evaluation of nonsmall cell lung cancer patient-derived xenograft models using 18F-FDG PET: a potential tool for early therapy response. J Nucl Med. 2017;58(1):42-7.

32. Kim HY, Kim J, Ha TH, Bang OS, Lee WS, Hong S. Evaluation of anti-tumorigenic activity of BPB against colon cancer with patient-derived tumor xenograft model. BMC Complement Altern Med. 2016;16(1):473.

33. Sivanand S, Pena-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamazi S, McBride DJ, Gillen J, Wolff NC, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med. 2012;4(137):137ra75.

34. Whittle JR, Lewis MT, Lindeman GJ, Visvader JE. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015;17(1).

35. Valtorta S, Mero M, Prisinzano G, Bertolini G, Tomoreto M, Raccagni I, Pastorino U, Roz L, Sozzi G, Moreo RM. Metabolic evaluation of nonsmall cell lung cancer patient-derived xenograft models using 18F-FDG PET: a potential tool for early therapy response. J Nucl Med. 2017;58(1):42-7.